ArticleRadiology2022
Local Extent of Prostate Cancer at MRI versus Prostatectomy Histopathology: Associations with Long-term Oncologic Outcomes.
Open access · greenAbstract read
In one paragraph
Article in Radiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
3.4field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 37 citations in OpenAlex.
- ESR Essentials: MRI-based T-staging in prostate cancer-practice recommendations by the European Society of Urogenital Radiology.European radiology · 2026Review
- Imaging-based clinical decision tree enables risk stratification of extraprostatic extension before radical prostatectomy in prostate cancer patients.Insights into imaging · 2026Article
- Navigating discordant findings in multimodality imaging of prostate cancer in the MRI and PSMA-PET era.La Radiologia medica · 2026Review
- Integrating biparametric MRI radiomics with clinical variables improves pre-treatment prediction of prostate cancer recurrence.Frontiers in oncology · 2026Article
- Evaluating extraprostatic extension of prostate cancer: pragmatic integration of MRI and PSMA-PET/CT.Abdominal radiology (New York) · 2025Article
- Development and evaluation of a lymph node invasion risk prediction model in intermediate- and high-risk prostate cancer patients.Acta oncologica (Stockholm, Sweden) · 2025Article
- Prognostic significance of the mEPE score in intermediate-risk prostate cancer patients undergoing ultrahypofractionated robotic SBRT.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2025Article
- Article
- MRI characteristics predict risk of pathological upgrade in patients with ISUP grade group 1 prostate cancer.European radiology · 2025Article
- Applying prediction models in clinical practice: the importance of fine details.Prostate cancer and prostatic diseases · 2024Article
- Impact of prostate MRI image quality on diagnostic performance for clinically significant prostate cancer (csPCa).Abdominal radiology (New York) · 2024Article
- Automated Detection and Grading of Extraprostatic Extension of Prostate Cancer at MRI via Cascaded Deep Learning and Random Forest Classification.Academic radiology · 2024Article
- Article
- Comparison of MRI-Based Staging and Pathologic Staging for Predicting Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy.AJR. American journal of roentgenology · 2023Article
- Evaluating residual tumor after neoadjuvant chemotherapy for muscle-invasive urothelial bladder cancer: diagnostic performance and outcomes using biparametric vs. multiparametric MRI.Cancer imaging : the official publication of the International Cancer Imaging Society · 2023Article
- Article
- [Systematic or targeted fusion-guided biopsy].Urologie (Heidelberg, Germany) · 2023Review
- The role of MRI in prostate cancer: current and future directions.Magma (New York, N.Y.) · 2022Review
- Artificial intelligence in oncologic imaging.European journal of radiology open · 2022Article
- Less qualitative multiparametric magnetic resonance imaging in prostate cancer can underestimate extraprostatic extension in higher grade tumors.International braz j urol : official journal of the Brazilian Society of UrologyArticle
Corrections and comments
- Commented on by
Authors and funding
11 authors at 2 institutions in 2 countries.
Andreas G WibmerFrom the Department of Radiology (A.G.W., I.N., J.C., Y.L., R.A.L., E.S., H.H., H.A.V.), Department of Epidemiology and Biostatistics (S.V.C.), Department of Surgery, Urology Service (S.V.C.), and Department of Pathology (S.W.F.), Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065; Institute of Clinical Sciences, Department of Urology, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden (S.V.C.); and Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio (M.W.K.).ORCID 0000-0003-3432-6706
Ines NikolovskiFrom the Department of Radiology (A.G.W., I.N., J.C., Y.L., R.A.L., E.S., H.H., H.A.V.), Department of Epidemiology and Biostatistics (S.V.C.), Department of Surgery, Urology Service (S.V.C.), and Department of Pathology (S.W.F.), Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065; Institute of Clinical Sciences, Department of Urology, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden (S.V.C.); and Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio (M.W.K.).ORCID 0000-0002-0690-1411
Joshua ChaimFrom the Department of Radiology (A.G.W., I.N., J.C., Y.L., R.A.L., E.S., H.H., H.A.V.), Department of Epidemiology and Biostatistics (S.V.C.), Department of Surgery, Urology Service (S.V.C.), and Department of Pathology (S.W.F.), Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065; Institute of Clinical Sciences, Department of Urology, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden (S.V.C.); and Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio (M.W.K.).ORCID 0000-0001-9413-7507
Yulia LakhmanFrom the Department of Radiology (A.G.W., I.N., J.C., Y.L., R.A.L., E.S., H.H., H.A.V.), Department of Epidemiology and Biostatistics (S.V.C.), Department of Surgery, Urology Service (S.V.C.), and Department of Pathology (S.W.F.), Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065; Institute of Clinical Sciences, Department of Urology, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden (S.V.C.); and Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio (M.W.K.).ORCID 0000-0003-3626-4502
Robert A LefkowitzFrom the Department of Radiology (A.G.W., I.N., J.C., Y.L., R.A.L., E.S., H.H., H.A.V.), Department of Epidemiology and Biostatistics (S.V.C.), Department of Surgery, Urology Service (S.V.C.), and Department of Pathology (S.W.F.), Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065; Institute of Clinical Sciences, Department of Urology, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden (S.V.C.); and Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio (M.W.K.).
Evis SalaFrom the Department of Radiology (A.G.W., I.N., J.C., Y.L., R.A.L., E.S., H.H., H.A.V.), Department of Epidemiology and Biostatistics (S.V.C.), Department of Surgery, Urology Service (S.V.C.), and Department of Pathology (S.W.F.), Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065; Institute of Clinical Sciences, Department of Urology, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden (S.V.C.); and Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio (M.W.K.).ORCID 0000-0002-5518-9360
Sigrid V CarlssonFrom the Department of Radiology (A.G.W., I.N., J.C., Y.L., R.A.L., E.S., H.H., H.A.V.), Department of Epidemiology and Biostatistics (S.V.C.), Department of Surgery, Urology Service (S.V.C.), and Department of Pathology (S.W.F.), Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065; Institute of Clinical Sciences, Department of Urology, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden (S.V.C.); and Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio (M.W.K.).ORCID 0000-0003-3553-5710
Samson W FineFrom the Department of Radiology (A.G.W., I.N., J.C., Y.L., R.A.L., E.S., H.H., H.A.V.), Department of Epidemiology and Biostatistics (S.V.C.), Department of Surgery, Urology Service (S.V.C.), and Department of Pathology (S.W.F.), Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065; Institute of Clinical Sciences, Department of Urology, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden (S.V.C.); and Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio (M.W.K.).ORCID 0000-0002-4322-3736
Michael W KattanFrom the Department of Radiology (A.G.W., I.N., J.C., Y.L., R.A.L., E.S., H.H., H.A.V.), Department of Epidemiology and Biostatistics (S.V.C.), Department of Surgery, Urology Service (S.V.C.), and Department of Pathology (S.W.F.), Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065; Institute of Clinical Sciences, Department of Urology, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden (S.V.C.); and Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio (M.W.K.).ORCID 0000-0002-3840-4161
Hedvig HricakFrom the Department of Radiology (A.G.W., I.N., J.C., Y.L., R.A.L., E.S., H.H., H.A.V.), Department of Epidemiology and Biostatistics (S.V.C.), Department of Surgery, Urology Service (S.V.C.), and Department of Pathology (S.W.F.), Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065; Institute of Clinical Sciences, Department of Urology, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden (S.V.C.); and Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio (M.W.K.).ORCID 0000-0003-2240-9694
Hebert Alberto VargasFrom the Department of Radiology (A.G.W., I.N., J.C., Y.L., R.A.L., E.S., H.H., H.A.V.), Department of Epidemiology and Biostatistics (S.V.C.), Department of Surgery, Urology Service (S.V.C.), and Department of Pathology (S.W.F.), Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065; Institute of Clinical Sciences, Department of Urology, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden (S.V.C.); and Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio (M.W.K.).ORCID 0000-0003-1169-133X
Memorial Sloan Kettering Cancer Center · USCleveland Clinic · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MIMAGING IN RISK ASSESSMENT OF PROSTATE CANCER PATIENTSR01CA076423 · NCI · UNIVERSITY OF CALIFORNIA SAN FRANCISCO · PI HRICAK, HEDVIG · 1999 to 2010
$2.3MImproving shared decision making in cancer screeningK22CA234400 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI CARLSSON, SIGRID · 2019 to 2021
$621kNCI NIH HHS K22 CA234400NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA076423
Abstract
Background It is unknown how the imperfect accuracy of MRI for local staging of prostate cancer relates to oncologic outcomes. Purpose To analyze how staging discordances between MRI and histopathologic evaluation relate to recurrence and survival after radical prostatectomy. Materials and Methods Health Insurance Portability and Accountability Act-compliant retrospective analysis of preprostatectomy T2-weighted prostate MRI (January 2001 to December 2006). Extraprostatic extension and seminal vesicle invasion were assessed by using five-point Likert scales; scores of 4 or higher were classified as positive. Biochemical recurrence (BCR), metastases, and prostate cancer-specific mortality rates were estimated with Kaplan-Meier and Cox models. Results A total of 2160 patients (median age, 60 years; interquartile range, 55-64 years) were evaluated. Among patients with histopathologic extraprostatic (pT3) disease (683 of 2160; 32%), those with organ-confined disease at MRI (384 of 683; 56%) experienced better outcomes than those with concordant extraprostatic disease at MRI and pathologic analysis: 15-year risk for BCR, 30% (95% CI: 22, 40) versus 68% (95% CI: 60, 75); risk for metastases, 14% (95% CI: 8.4, 24) versus 32% (95% CI: 26, 39); risk for prostate cancer-specific mortality, 3% (95% CI: 1, 6) versus 15% (95% CI: 9.5, 23) (
Indexed as
HumansMagnetic Resonance ImagingMaleMiddle AgedNeoplasm Recurrence, LocalNeoplasm StagingProstatectomyProstatic NeoplasmsRetrospective StudiesSensitivity and Specificity
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.